BMO Capital downgraded Bristol-Myers Squibb Co. (NYSE: BMY) from Outperform to Market Perform with a price target of $70.00 (from ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE